The entire focus of the healthcare system has been on COVID-19 for quite a few months now. Most of the resources have been assigned to tackle the pandemic while other segments in this segment have been left out. Diagnosing other diseases has been sidelined, but with new testing methods cropping up, we could witness renewed momentum in this sector. Exact Sciences Corporation (EXAS), a company offering cancer screening and diagnostic products, has been facing pressure on its revenues due to the pandemic but has managed to show positive signs as the stock trades